Facial palsy Revealing AR+/HER2+ Parotid carcinoma and the efficacy of HER2-Targeted therapy trastuzumab deruxtecan
Tiffany Ng1, Momilani Tupu1, Naidelin Maldonado2
1Touro University Nevada College of Osteopathic Medicine, 874 American Pacific Drive, Henderson, NV 89014, United States of America.
Abstract:
Salivary duct carcinomas present challenges to diagnosis and treatment due to diversity in histopathology and clinical behavior (Laurie & Licitra, 2006; Seethala, 2009). A 76-year-old male presented with gradual left-sided facial weakness that was discovered to be left parotid malignant salivary gland carcinoma. Treatment with fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody-drug conjugate, produced a favorable response. Results support an emerging "HER2-low" treatment protocol across diverse salivary gland malignancies.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
